CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fiddes, R. J.
Right arrow Articles by Daly, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fiddes, R. J.
Right arrow Articles by Daly, R. J.

Cell Growth & Differentiation, Vol 6, Issue 12 1567-1577, Copyright © 1995 by American Association of Cancer Research


ARTICLES

Heregulin (HRG)-induced mitogenic signaling and cytotoxic activity of a HRG/PE40 ligand toxin in human breast cancer cells

RJ Fiddes, PW Janes, GM Sanderson, SP Sivertsen, RL Sutherland and RJ Daly
Co-operative Research Centre for Biopharmaceutical Research, Garvan Institute of Medical Research, St. Vincent's Hospital, Sydney, New South Wales, Australia.

The heregulins (HRGs) are a family of growth factors that bind direction to erbB3 and erbB4 and induce tyrosine phosphorylation of erbB2 via receptor heterodimerization. Since erbB2, erbB3, and erbB4 (erbB2-4) are often overexpressed in human breast cancer cells, we produced recombinant HRGs and a HRG-based ligand toxin to investigate the signaling events triggered by HRGs and the ability of these ligands to specifically target such cells. Recombinant HRG beta 2 stimulated the tyrosine phosphorylation of erbB2-4 in ZR-75-1 human breast cancer cells. This was accompanied by the tyrosine phosphorylation of Shc and the formation of complexes between Shc and the adapter protein Grb2. Complexes were also detected between Shc and erbB2-4. However, GRb2 was detected in erbB2 and erbB4 but not erbB3 immunoprecipitates. Thus, these receptors exhibit mechanistic differences in their coupling to Ras signaling, and HRG beta 2 administration triggers multiple inputs into the Ras signaling pathway, involving receptor-Grb2, receptor-Shc, and Shc-Grb2 complexes. HRG beta 2 addition also stimulated the association of erbB3 with phosphatidylinositol-3-kinase. In accordance with the activation of key mitogenic signaling pathways, HRG beta 2 stimulated the proliferation of MCF-7 and T-47D human breast cancer cells. Moreover, when tested for the ability to stimulate cell cycle re-entry of T-47D cells arrested under serum-free conditions, HRG beta 2 was more effective than insulin, previously the most potent mitogen identified using this system. Finally, a HRG beta 2 PE40 ligand toxin was constructed and found to exhibit cytotoxic activity against human breast cancer cells overexpressing erbB3 alone or in combination with erbB4 and/or erbB2.


This article has been cited by other articles:


Home page
DevelopmentHome page
F. A. Stennard, M. W. Costa, D. Lai, C. Biben, M. B. Furtado, M. J. Solloway, D. J. McCulley, C. Leimena, J. I. Preis, S. L. Dunwoodie, et al.
Murine T-box transcription factor Tbx20 acts as a repressor during heart development, and is essential for adult heart integrity, function and adaptation
Development, May 15, 2005; 132(10): 2451 - 2462.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
A. Swarbrick, C. S. L. Lee, R. L. Sutherland, and E. A. Musgrove
Cooperation of p27Kip1 and p18INK4c in Progestin-Mediated Cell Cycle Arrest in T-47D Breast Cancer Cells
Mol. Cell. Biol., April 1, 2000; 20(7): 2581 - 2591.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
R. J. Fiddes, D. H. Campbell, P. W. Janes, S. P. Sivertsen, H. Sasaki, C. Wallasch, and R. J. Daly
Analysis of Grb7 Recruitment by Heregulin-activated erbB Receptors Reveals a Novel Target Selectivity for erbB3
J. Biol. Chem., March 27, 1998; 273(13): 7717 - 7724.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1995 by the American Association of Cancer Research.